Michael Huber, MD
Cardiovascular Disease · Little Rock, ARNPI 1619948700
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,338 of the $12,003 with a category attached, or 86.1%. 18 manufacturers reported payments, led by Boehringer Ingelheim at 55.7% of the total. Reporting peaked in 2021 at $7,422 and has fallen 98.2% since, to $130 in 2025.
Across 88 payments — averaging $136.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$7K
- Lilly USA, LLC$4K
- Abbott$426
- Pfizer$286
- E.r. Squibb & Sons, L.L.C.$109
- Merck$94
- plus $467 from 12 others
Across 13 payments — averaging $2887.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$37K
- American Regent$570
What the payments were for
- Speaking & faculty fees$10,33886%
- Food & beverage$1,61913%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 10 | $6,683 |
| Lilly USA, LLC | 5 | $3,938 |
| Abbott | 15 | $426 |
| Pfizer | 18 | $286 |
| E.r. Squibb & Sons, L.L.C. | 8 | $109 |
| Merck | 5 | $94 |
| Johnson & Johnson | 4 | $90 |
| Amgen | 3 | $62 |
| Lexicon Pharmaceuticals, Inc. | 4 | $59 |
| AstraZeneca | 4 | $55 |
| Novartis | 2 | $33 |
| Chiesi USA, Inc. | 2 | $30 |
| Scpharmaceuticals Inc. | 2 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Boston Scientific | 2 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$10,575
- MitraClip System$121
How this compares
$12,003 in reported general payments places this provider in the 80th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 801 | $605,820 |
| EntrestoSacubitril/Valsartan | 199 | $174,106 |
| XareltoRivaroxaban | 206 | $154,198 |
| JardianceEmpagliflozin | 162 | $105,833 |
| FarxigaDapagliflozin Propanediol | 78 | $52,324 |
| MultaqDronedarone Hcl | 31 | $25,112 |
| BrilintaTicagrelor | 43 | $24,347 |
| Repatha SyringeEvolocumab | 19 | $16,782 |
| Repatha SureclickEvolocumab | 24 | $13,150 |
| Metoprolol Succinate | 826 | $8,793 |
| VascepaIcosapent Ethyl | 17 | $7,001 |
| Praluent PenAlirocumab | 13 | $6,410 |
| Ranolazine ErRanolazine | 75 | $4,995 |
| Atorvastatin Calcium | 491 | $4,024 |
| Rosuvastatin Calcium | 311 | $3,892 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $286 | $605,820801 claims |
| NovartisEntresto | $33 | $174,106199 claims |
| Johnson & JohnsonXarelto | $90 | $154,198206 claims |
| Boehringer IngelheimJardiance | $6,683 | $105,833162 claims |
| AstraZenecaFarxiga, Brilinta | $55 | $76,671121 claims |
| Sanofi-aventis U.S. LLCMultaq | $22 | $25,11231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in Little Rock
- Ian CawichLittle Rock$294K
- William RollefsonLittle Rock$74K
- Andre PaixaoLittle Rock$73K
- Wesley LaneLittle Rock$46K
- Omar QaqishLittle Rock$45K
- Barry UretskyLittle Rock$36K
- Freddy ChrismanLittle Rock$26K
- Forrest GloverLittle Rock$17K
- Clayton BorgLittle Rock$14K
- David MegoLittle Rock$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.